Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Resmed Inc (RMD)

Resmed Inc (RMD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 39,570,516
  • Shares Outstanding, K 145,678
  • Annual Sales, $ 5,146 M
  • Annual Income, $ 1,401 M
  • EBIT $ 1,868 M
  • EBITDA $ 2,103 M
  • 60-Month Beta 0.87
  • Price/Sales 7.56
  • Price/Cash Flow 23.84
  • Price/Book 6.15

Options Overview Details

View History
  • Implied Volatility 25.77% (+0.10%)
  • Historical Volatility 22.32%
  • IV Percentile 29%
  • IV Rank 14.90%
  • IV High 56.66% on 04/08/25
  • IV Low 20.36% on 08/13/25
  • Expected Move (DTE 11) 10.63 (3.88%)
  • Put/Call Vol Ratio 0.75
  • Today's Volume 958
  • Volume Avg (30-Day) 588
  • Put/Call OI Ratio 2.64
  • Today's Open Interest 16,902
  • Open Int (30-Day) 15,148
  • Expected Range 262.91 to 284.16

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 19 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate 2.77
  • Number of Estimates 6
  • High Estimate 2.84
  • Low Estimate 2.69
  • Prior Year 2.37
  • Growth Rate Est. (year over year) +16.88%

Price Performance

See More
Period Period Low Period High Performance
1-Month
245.21 +11.60%
on 01/30/26
274.07 -0.15%
on 02/09/26
+21.18 (+8.39%)
since 01/09/26
3-Month
237.63 +15.16%
on 12/01/25
274.07 -0.15%
on 02/09/26
+22.16 (+8.81%)
since 11/07/25
52-Week
199.92 +36.88%
on 04/07/25
293.81 -6.86%
on 08/22/25
+36.71 (+15.50%)
since 02/07/25

Most Recent Stories

More News
The Top 5 Analyst Questions From ResMed’s Q4 Earnings Call

The Top 5 Analyst Questions From ResMed’s Q4 Earnings Call

RMD : 273.99 (+0.87%)
RMD Q4 Deep Dive: Mask Innovation and Digital Health Expansion Drive Growth

RMD Q4 Deep Dive: Mask Innovation and Digital Health Expansion Drive Growth

RMD : 273.99 (+0.87%)
ResMed (NYSE:RMD) Exceeds Q4 CY2025 Expectations

ResMed (NYSE:RMD) Exceeds Q4 CY2025 Expectations

RMD : 273.99 (+0.87%)
ResMed: Fiscal Q2 Earnings Snapshot

ResMed: Fiscal Q2 Earnings Snapshot

RMD : 273.99 (+0.87%)
Resmed Inc. Announces Results for the Second Quarter of Fiscal Year 2026

Revenue increased by 11% to $1.4 billion; up 9% on a constant currency basis  Gross margin up 320 bps to 61.8%; non-GAAP gross margin up 310 bps to 62.3% Income from operations increased 18%; non-GAAP income...

RMD.AX : 38.450 (+1.40%)
RMD : 273.99 (+0.87%)
ResMed (RMD) To Report Earnings Tomorrow: Here Is What To Expect

ResMed (RMD) To Report Earnings Tomorrow: Here Is What To Expect

RMD : 273.99 (+0.87%)
1 Safe-and-Steady Stock Worth Investigating and 2 We Find Risky

1 Safe-and-Steady Stock Worth Investigating and 2 We Find Risky

CPB : 28.67 (-0.55%)
RMD : 273.99 (+0.87%)
LAD : 333.79 (-3.04%)
Reflecting On Patient Monitoring Stocks’ Q3 Earnings: ResMed (NYSE:RMD)

Reflecting On Patient Monitoring Stocks’ Q3 Earnings: ResMed (NYSE:RMD)

RMD : 273.99 (+0.87%)
ResMed (RMD): Buy, Sell, or Hold Post Q3 Earnings?

ResMed (RMD): Buy, Sell, or Hold Post Q3 Earnings?

RMD : 273.99 (+0.87%)
Resmed to Report Second Quarter Fiscal 2026 Earnings on January 29, 2026

SAN DIEGO, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the second quarter of fiscal year 2026 on Thursday,...

RMD.AX : 38.450 (+1.40%)
RMD : 273.99 (+0.87%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

ResMed, Inc. holds a major position as designer, manufacturer, as well as a distributor in the worldwide market for generators, masks, and related accessories for the treatment of sleep-disordered breathing (SDB) and other respiratory disorders. SDB includes obstructive sleep apnea (OSA) and other respiratory...

See More

Key Turning Points

3rd Resistance Point 278.93
2nd Resistance Point 275.63
1st Resistance Point 273.63
Last Price 273.99
1st Support Level 268.33
2nd Support Level 265.03
3rd Support Level 263.03

See More

52-Week High 293.81
Last Price 273.99
Fibonacci 61.8% 257.94
Fibonacci 50% 246.86
Fibonacci 38.2% 235.79
52-Week Low 199.92

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar